Stealth Adapted Viruses Linked To Autism and
Other Diseases
Posted on Mar 18, 2005
Ms. April Oakes, President of TAAP
Author: W. John Martin, M.D., Ph.D.
Source: The Autism Autoimmunity Project (TAAP)
A lot of effort and resources within the autism community
have been misdirected. Consequently, the epidemic continues.
I am very confident autism will eventually be recognized as
having a viral cause. This delay will be lessened if parents
simply consider the facts and sort through the political and
economic agendas that bias what they are mainly being
presented.
The important facts are:
1. The cellular immune system does not effectively recognize
all viruses. Effective immune recognition is generally
restricted to only a few viral components. For example
cytomegalovirus (a type of herpesvirus) has nearly 200
proteins yet over 90% of the cytotoxic T cell immune
response is directed to only 3 viral components. By a
process called "stealth-adaptation" a virus can lose these
critical components and yet can retain or regain the ability
to cause cell damage. I have DNA sequence data confirming
this mechanism. More importantly, I have directly observed
animals inoculated with stealth adapted viruses. The animals
become extremely sick with widespread tissue damage,
including extensive damage to the brain. Yet there is no
inflammatory response; the usual hallmark of an infectious
process. I have seen similar brain damage in several
patients from whom I have cultured cell damaging (cytopathic)
viruses. Interestingly, the animals largely recover from
their illness over time (discussed later).
2. Unlike other organs in the body, the brain is uniquely
sensitive to virus induced cell damage. With other organs,
there is an overall uniform function. This means that
limited localized damage in one area of these organs can be
easily compensated by increased activity elsewhere. The
brain functions differently with specific functions
localized to distinct areas. Damage in one area cannot,
therefore, be easily overcome. An exception is when the
virus induces an auto-immune response such as in Hasimoto's
disease of the thyroid which is not uncommon among stealth
virus infected patients. The other exception is cancer which
only requires a single cell to go astray.
3. The big political block to my work came when I announced
in 1995 that the prototype stealth-adapted cytomegalovirus
was not of human origin, but was derived from the monkeys
used to make live polio virus vaccines. I immediately
notified FDA, CDC and Wyeth the manufacturer of live polio
virus vaccine, but received a very cold reception. Adding to
this block was the undisclosed study performed by FDA and
Industry in 1972 showing that all of the African green
monkeys being used for polio vaccine production were
infected with simian cytomegalovirus (SCMV). FDA and
Industry failed to disclose this finding not contemplating
that viruses could cause chronic illnesses.
4. FDA recently did locate 8 licensed lots of polio vaccines
released to the public in 1976. Three of the 8 lots have DNA
of SCMV. FDA investigators say they cannot culture live
virus from these lots, nor can they legally provide them for
outside testing. in spite of this finding, FDA officials are
still reluctant to follow up on my initial reports of
stealth-adapted SCMV being isolated both from a patient with
chronic fatigue syndrome and from a patient with a bi-polar
manic depressive psychiatric illness.
5. It is technically difficult to culture stealth-adapted
viruses because of a tendency for the cell damaging effect
not to progress. The cultures undergo a repair process
because of materials that accumulate in the culture fluids.
I now recognize that these materials provide an alternative
(non-mitochondria) source of cellular energy.
6. The polymerase chain reaction (PCR) can be used to detect
some stealth-adapted viruses providing the small region
being targeted by this reaction is conserved. Another
difficulty with the PCR assay is that not all
stealth-adapted viruses are derived from SCMV. Rather
stealth-adaptation is a generic process that presumably can
occur with all types of cytopathic viruses, e.g. EBV, HHV-6,
HSV, etc.
7. An individual from Florida recently sent his own and his
father's blood to an animal testing laboratory. He had the
smarts to pretend to be a veterinarian and to request tests
on supposedly monkey blood. The result came back PCR
positive for SCMV. I visited the testing lab. and assured
myself they were able to clearly exclude human, rhesus
monkey and baboon CMV and that the result was indeed
positive for SCMV. The infected patient notified CDC of the
results. CDC simply concluded they could not culture
virus from his blood and the issue has seemingly been
dropped. I received a "legal
request" from the patient to test his blood. It induced the
characteristic cytopathic effect caused by stealth-adapted
viruses..
8. The Florida example underscores the infectious nature of
stealth-adapted viruses. The gentleman became infected
during a trip and soon after returning home saw marked
behavioral changes in his son. His father visited briefly
and he too became sick. There are many examples of "family
illnesses of presumptive infectious origin" including many
families in which there is an autistic child. The gentleman
has markedly improved on ACE products (discussed below).
9. I have previously performed several double blind studies
comparing stealth virus cultures from patients with various
illnesses, including autism, with blood samples from
volunteer donating blood for transfusions. A clear
distinction was seen with the vast majority of patients
testing positive compared to 10-15% of blood donors.
According to the terms of the approved study, I could obtain
no information on the health of those blood donors who
tested positive. The implication of a contaminated National
blood supply was hard for Public Health authorities to
accept. In late 2002 I was encouraged (instructed) not to
perform any further clinical testing and to ensure my
compliance the clinical testing laboratory license was
suspended. The only exceptions allowed were for research
and, as I have recently learned, if legally requested.
10. The research focus returned to the issue that if there
was no effective immune recognition, how does the body cope
with stealth-adapted viruses. The answer was in the cultures
that showed complete healing if inhibitory materials were
allowed to accumulate. I had previously noted unusual
complex structures in the brain cells of humans and
stealth-virus inoculated animals. The mitochondria which
normally supply the cell with energy were markedly
disrupted, yet the cells were still surviving. It appeared
as if the complex structures, and the materials accumulating
in the cultures, were providing an alternative
(non-mitochondria) source of cellular energy. I called these
structures alternative cellular energy pigments (ACE
pigments). ACE pigments were experimentally shown to provide
an auxiliary defense mechanism that is particularly relevant
in defending against stealth-adapted viruses.
11. The importance of the ACE pathway has been convincingly
demonstrated in the ease of therapy for conventional HSV
oral and genital lesions. The ACE pathway in these lesions
can be easily activated using a dye called neutral red
followed by brief exposure to ultraviolet-A light. This
approach also works well with shingles and post herpetic
neuralgia and with genital warts caused by human
papillomavirus. FDA was notified of these findings last
October and are still trying to decide if they want to
classify neutral red as a drug or as a medical device.
12. The obvious implication for autistic children is to
activate and/or support the ACE pathway. I have been
impressed with some preliminary responses and now want to
see controlled studies. The current format for the herpes
treatment is to have patients select a physician of their
choice. The physicians are to evaluate the lesions before
and the day after therapy. We can compensate the physician
up to 0.00 from fees collected from participants willing to
join an Institute of Progressive Medicine. I think we should
do the same with autistic children.
13. It is clear that the pharmaceutical approach to many
chronic illnesses has its limitations. The public needs to
be better informed of developments outside the
pharmaceutical industry. Good data need to be collected from
well designed clinical trials.
14. I hope the foregoing will give a sense of optimism to
parents struggling with autism and related illnesses.
Research on stealth-adapted viruses has opened up a whole
new approach to disease therapy. I would like to encourage
individuals to visit the web site www.s3support.com and to
consider participating in clinical trials as one of the
bonuses of being a member of the Institute of Progressive
Medicine . The web site has copies of various publications
and supporting information.
15. Parents can also put political pressure on the system to
begin to address autism as an unintended consequence of
allowing cytomegaloviruses to contaminate polio vaccines.
Infected parents are at risk of having autistic children.
Such parents can be identified, but not if the Public Health
system will not allow stealth virus testing or acquire the
know-how to do this type of testing within their own
facilities. Kind regards, W. John Martin, M.D., Ph.D.
Posted May 11, 2005
Dear April,
Thanks for your expression of concern about the very limited
research support I am receiving. The real concern ought to
be for autistic children and their families. It is
disappointing to me that very few so called advocates for
these children are willing to acknowledge the potential role
of stealth-adapted viruses in causing autism. I used to
think it was my responsibility to convince others of what
appeared to me to be pretty obvious. That is, if autism is
epidemic one should suspect an infectious cause. A role for
stealth-adapted viruses was established in double blind
culture studies attested to by well qualified individuals.
Yet the data were not acted upon. When I offered to speak at
a local meeting in Los Angeles, I was bluntly told “You are
off message John;” meaning that I was not supporting mercury
as the cause of autism and not advocating expensive
laboratory tests or therapies with kick-backs to those
willing to wheel and deal. As I mentioned in an earlier
letter, it is truly disappointing when a speaker fresh from
receiving a standing ovation by appreciative parents is seen
conversing with colleagues on how to franchise a lucrative
scheme for generating exorbitant incomes. I rarely receive
requests from other investigators or patient advocates to
help explain stealth-adaptation or the concept of an
alternative (non-mitochondria) pathway of cellular energy.
Conversely my requests for an overview of laboratory results
to better understand how they influence therapy are met with
resistance. Similarly, the actual response rates to the
various therapies in terms of hard clinical data are rarely
provided. I would like to see a vigorous movement among
parents of autistic children to demand that their children
and other family members be tested in Public Health
facilities for infectious viruses. Whether they are called
stealth-adapted or something else, it is not difficult to
demonstrate their presence using methods that were published
over a decade ago. Some of the viruses will undoubtedly be
shown to have arisen from African green monkey simian
cytomegalovirus. This is consistent with FDA's own data of
DNA of this virus being present in 3 of 8 licensed polio
vaccine lots released in the mid 1970s. It also follows the
1972 realization that the monkeys being used to produce live
polio virus vaccine were uniformly infected with simian
cytomegalovirus. In retrospect, the use of freshly cultured
monkey kidney cells to produce polio vaccines may turn out
to be the biggest Public Health blunder of the last century.
Stealth-adaptation of cytomegalovirus and other viruses is
based on the simple concept that the cellular immune system
only recognizes and reacts to relatively few viral
components. In the case of human cytomegalovirus, over 90%
of the anti-virus cytotoxic T cells are directed at only 3
of the nearly 200 different components. Loss or mutation of
these critical components can allow a virus to evade
effective immune recognition. A present day analogy is that
of a terrorist who has no insignia or other means of
identification. Like a terrorist, stealth-adapted viruses
can still cause a lot of damage. It is mostly reflected by
impaired functioning of the brain which is especially
vulnerable to even limited localized cell damage.
Fortunately, the immune system is not the only defense
humans and animals have against virus infections. >From the
beginning of the research, it was apparent that if cultures
of stealth-adapted viruses were left undisturbed, the
damaged cells would recover. The recovery process was
attributed to the accumulation of what I termed alternative
cellular energy pigments (ACE pigments). Validation of this
approach has come from recently published studies showing
expedited healing of conventional herpes simplex and herpes
zoster viruses and also papillomavirus induced skin lesions
by activating the ACE pathway. I firmly believe that autism
will also be amenable to this type of approach. ACE
related therapies are not dependent upon there being an
underlying virus infection. On the other hand, mobilization
of Public Health resources in support of preventing and
treating autism will be more forthcoming to counter an
infectious process. I am open to suggestions and to offers
of help to move the process forward. This has been a
productive year in terms of publications with five peer
reviewed articles, four of which are on the web site
www.s3support.com. The article that I look forward to seeing
published this year will be one showing marked clinical
benefits in autistic and other stealth-adapted virus
infected children in response to activation of the ACE
pathway. With sufficient support and public awareness, I
feel this goal can be achieved. Kind regards, W. John
Martin, M.D., Ph.D. Posted May 15, 2005 Dear April I
received several enquiries in response to your posting a
letter that I had recently sent. Among the questions being
asked is why does CDC not believe in stealth-adapted viruses
and why was I prohibited from continuing to perform stealth
virus testing within the Center for Complex Infectious
Diseases. The CDC has plenty of justification to test for
stealth-adapted viruses but not the political will (meaning
direction from Congress) to do so. The basic challenge “If
autism is epidemic, why not look for an infectious cause?”
has never been vigorously pursued by public health
authorities. Your readers may be interested in the following
vignette. Last year an individual developed an apparent
infectious disease during a business trip. He initially
feared AIDS in spite of there being no close sexual
encounters. HIV tests were uniformly negative. His concerns
about being infectious increased when he noted marked
behavioral changes in his son. His father also started to
experience headaches, fatigue and memory loss following a
weekend visit. Having read of my work on simian
cytomegalovirus (SCMV), he inquired of the Miami Zoo how
they test for SCMV. They referred him to a primate testing
laboratory that performs polymerase chain reaction (PCR)
assays for various viruses. Having the smarts to adopt the
name of his neighbor's dog for his own blood sample and a
similar monkey sounding name for his father's blood, he
requested testing from the primate laboratory. Both results
came back positive for SCMV by PCR. I visited the laboratory
and was assured of the positive results that excluded human,
rhesus monkey or baboon CMV. Using the loophole that
forensic testing is exempt from the Clinical Laboratory
Improvement Act (CLIA) prohibition against unapproved
clinical tests, I confirmed, in response to a formal legal
request, that the individual was culture positive for a
stealth-adapted virus. CDC was contacted by the individual.
They did at least request blood and throat samples but did
not avail themselves of my offer to describe how best to
culture for stealth-adapted viruses. Not getting a positive
culture, CDC readily dropped the ball. The individual has
significantly benefited from products that can provide
support through the alternative cellular energy (ACE)
pathway. There are many other compelling reasons why CDC
should be more proactive in pursuing the potential of
widespread SCMV infection in the community. FDA has
published data showing that 3 of 8 licensed polio vaccines
released to the public in the mid 1970's contained DNA of
SCMV. Congenital infection with regular human
cytomegalovirus is one of the known causes of autism, being
all the more reason to look for stealth-adapted
cytomegalovirus. SCMV has multiple copies of a gene that
enhances the infectivity of HIV. CMV is also implicated in
major vascular diseases and in several forms of cancer.
Various autism support organizations have been remiss in
disregarding a potential infectious process as a major cause
for the autism epidemic. More than once I have heard it
argued “We don't want to go there less we give our children
a pariah status.” More likely, the notion of an infection
conjures an image of high fevers, inflammation and person to
person transmission of an illness. None of these apply to
autism. Nor do these parameters apply to stealth-adapted
viruses that avoid effective immune recognition and do not
provoke an inflammatory reaction. I have also been
personally criticized by a few individuals who seem to need
a focus for their anger. Negative comments, especially when
presented on the internet have assuredly discouraged others
from supporting my research and have played into the hands
of those not wanting to face the reality of stealth-adapted
viruses. In response to being asked once again to respond to
such criticisms, I provided one of your readers with the
following historical account. I thought it might be useful
for you to share it with other readers. Kind regards, John.
Dear Mr. ________, I have become pretty immune to
pointless criticisms and feel it is part of the territory of
working on a socially complex set of illnesses. An early
encounter with patient anger came at a talk I gave at the
University of Southern California (USC) in August 1994. I
had just published an extensive article in the American
Journal of Pathology that was entitled
“Cytomegalovirus-related sequences in an atypical cytopathic
virus repeatedly isolated from a patient with the chronic
fatigue syndrome.” A husband and wife team of prominent
academics from a major neighboring academic institution were
in attendance at my talk. The data were straightforward and
worth discussing. Instead the tenor of repeated
interruptions from the husband was along the lines, “I have
chronic fatigue and I am smarter than you. I do not know
what causes it, neither do you.” Rather than leaving it at
that, he complained to the dean who subsequently lectured me
on how the University fund raising efforts could be
undermined if I pursued divisive research. There was also
a hostile backlash from some prominent researchers within
the chronic fatigue and immune system dysfunction syndrome (CFIDS)
community. They had looked for viruses but had either not
found any or had dismissed what they saw as reflecting
secondary reactivation. Again, I was surprised by their
complaints going to the dean at USC. A CFIDS support group
had earlier wanted there to be a correlation between a
positive virus culture and the symptom of fatigue. When this
was not true they also withdrew support in favor of more
politically connected supporters. The research continued
and by 1995 I had unequivocally established that at least
two of the virus isolates were derived from the
cytomegalovirus of African green monkeys. These results were
published in an article appearing in July 1995 entitled
“African green monkey origin of the atypical cytopathic
'stealth virus' isolated from a patient with chronic fatigue
syndrome.” The same year I published a research letter
“Stealth virus isolated from an autistic child” and a
compelling paper along with Dr. Tom Glass entitled “Acute
encephalopathy induced in cats with a stealth virus isolated
from a patient with chronic fatigue syndrome.” The
clinical and microscopic observations made in the cats
paralleled those I had seen in severely ill patients with
undiagnosed neurological diseases. There was subtle but
extensive cell damage without any inflammation, the accepted
hallmark of an infectious process. As far back as 1990, I
had seen brain biopsies with no inflammation yet microscopic
indications of the same type of cellular damage as was
occurring in cultures from the blood and cerebrospinal
fluids from chronic fatigue syndrome patients as well as
from several children with autism and related illnesses.
Moreover, the brain tissue yielded evidence for a virus
infection using the polymerase chain reaction (PCR) assay.
Several of the cultures showed electron micrographic
evidence of virus activity along with peculiar material that
I had initially discounted as cellular debris. I soon came
to realize that this material was actually helping the
cultures overcome the cell damaging effects caused by the
viruses and knew that it might provide a clue on how to
eventually treat patients infected with these viruses. I
called these materials Epione after the wife of Asclepius,
the father of Greek medicine. The African green monkey
origin of some of isolated stealth-adapted viruses
implicated live polio virus vaccine produced in kidney cell
cultures from these monkeys as the probable source. Having
worked at the FDA Bureau of Biologics, I was well aware of
the vaccine production method and the continuing concerns
about virus contaminants. My notifications to FDA, CDC and
the vaccine manufacturer were not kindly received. Moreover,
my offers to test chronic fatigue syndrome patients for
evidence of monkey virus infection exceeded the threshold at
USC. My laboratory was closed within a week of a lawyer
filing a suit against the polio vaccine manufacturer for me
to test some of the bulk lots of vaccines received by his
ill clients. Having seen numerous examples of virus
culture positive patients struggling with their illnesses, I
was unwilling and indeed unable to sign an agreement with
USC not to test any additional patient samples. The research
proceeded quietly and at a slow pace in a private largely
self-supported laboratory. At critical times an occasional
person appeared who helped bridge a critical financial gap.
I once called a Japanese donor who had provided some steady
support to express my deep appreciation. His simple answer
“It is my duty,” reinforced my own conviction that I was
obligated to proceed with the research. In 2003 I again
crossed a threshold by stating that up to ten percent of
students donating blood to the UC Irvine Blood Bank were
stealth virus positive. This brought into question the
safety of the nation's blood supply. Of several hundred
patient contacts, all but a few have been very rewarding and
have more than encouraged my continuing efforts on their
behalf. I have encountered the occasional hostile patient
with a sense of anger, resentment, self-entitlement and
betrayal when I have not endorsed an unjustified demand. One
such patient was used by the California Department of Health
to carry out the wish of the Centers for Disease Control and
Prevention (CDC) to stop patient testing for stealth-adapted
viruses. This was achieved by suspending a Clinical
Laboratory Improvement Act (CLIA) laboratory license in
September 2002. Copies of my fruitless letters to the
Centers for Medicare and Medicaid that issues CLIA licenses
are included on the web site www.s3support.com Fueled by
the suspension of the CLIA license, the patient went on to
file legal suits and make extraordinarily disparaging claims
in a television interview. While I answered many leading and
insulting telephone questions from a reporter from NBC, I
chose not to grant her a filmed interview. My experience at
USC had convinced me that major news organizations were
unlikely to fairly air an opinion that polio vaccines were a
potential source of many of today's epidemic illnesses. The
bad publicity from the television showing was used by a
splinter CFIDS group to declare on the internet that all
stealth virus-related research was bogus. I have similarly
been criticized for not endorsing various co-infections of
patients with pathogens such as mycoplasma, HHV-6, Borrelia
(the bacterium that causes Lyme disease) or with toxins,
such as mercury in the case of autism. The criticisms have
only come after an overture for me to join in and share a
piece of their pie. I am more comfortable staying with what
I know to be true. Viruses do exist that are not effectively
recognized by the immune system. These viruses can be
frequently cultured from patients with chronic debilitating
neurological illnesses. Some of these viruses were
unequivocally derived from the cytomegalovirus of the
monkeys used to produce live polio virus vaccines. That the
body can use a non-immunological defense mechanism to
provide an alternative (non-mitochondria) source of cellular
energy; and that this alternative cellular energy (ACE)
pathway explains the repair process seen in cultures of
stealth-adapted viruses. This pathway offers a promising
approach to therapy of stealth-adapted viruses as well as an
adjunct approach to therapy of conventional viruses such as
herpes simplex, herpes zoster and human papillomavirus
infections. Five papers have been submitted or published
this year with several more in preparation. The research is
providing interesting insights into basic biology and has
important therapeutic and public health ramifications. It
could benefit from more support and less criticism. I trust
this answers your concerns.
Kind regards, W. John Martin, M.D., Ph.D.
Posted Oct. 22, 2005
Dear April,
I was helping someone prepare for an upcoming
interview by providing answers to possible questions. I am
happy to share the material with members of TAAP.
Is there evidence that the increasing prevalence of chronic
illnesses has an infectious and, therefore, transmissible,
contagious component and, if so, why is it not being
recognized.
Answer.
There is an inadequacy of epidemiological methods to
identify an infectious process causing chronic multifaceted
diseases. An infectious process is consistent with the
patterns of family illnesses and with larger community
outbreaks.
What type of infection do you think is the probable cause of
these diseases?
Answer.
Cell damaging viruses that can cause a persisting illness,
explained in part by the inability of the immune system to
effectively recognize viruses that have deleted or mutated
genes coding for the relatively few viral components
targeted by the immune system. (A process that I have called
stealth-adaptation). These
viruses can be cultured and can cause disease in animals.
Where have some of these stealth-adapted viruses come from?
Answer.
African green monkey simian cytomegalovirus SCMV. (CMV is a
type of herpes virus). Published evidence from FDA of SCMV
contamination of polio vaccines produced in kidney cell
cultures from African green
monkeys. Stealth-adaptation can potentially occur with any
type of cell damaging virus.
If the immune system does not respond to stealth-adapted
viruses, how is it possible for the body to control an
infection.
Answer.
The body uses an auxiliary defense mechanism whereby cells
acquire needed energy from an alternative (non-mitochondria)
cellular energy pathway. This pathway involves the
conversion of physical energies
into cellular energy by materials I have called alternative
cellular energy pigments. Activation of these pigments can
have therapeutic benefits, as can providing products with
ACE activity.
Some stealth-adapted virus infected patients release ACE
pigments in perspiration and from skin lesions. Patients
mistake them for parasites and can be labeled as having
delusional parasitosis. Other
stealth-adapted viruses can assimilate bacterial sequences
leading to positive assays for various types of bacteria,
including Borrelia (the cause of acute Lyme disease),
mycoplasma (a suspected cause of
Gulf War Syndrome).
Ongoing emphasis is on controlled clinical trials. Striking
benefits were seen with therapy of conventional herpes
simplex and herpes zoster virus infections. Energy based
therapy also markedly improved
outcome of children with tropical diahhrea (study done in El
Salvador to be presented at the American society of Tropical
Medicine and Hygiene Meeting in New York, December 15,
2005).
What is CDC's position on stealth-adapted viruses.
Answer.
They are unwilling to test for these viruses and hide behind
the argument that others have not confirmed their existence.
In fact, there are data supporting the underlying concept
from several recent studies. CDC
has been notified on individuals testing positive for SCMV
using the polymerase chain reaction (PCR). Some of those
working at CDC are aware of the Public Health consequences
of acknowledging stealth-adapted viruses. Unfortunately,
they are not in a position of authority.
Why did you stop testing for stealth-adapted viruses?
With input from CDC, our license for testing for these
viruses was suspended by the Government in late 2002. All of
the methods have been published and provided to Public
Health authorities. It is really their
responsibility to pursue infectious causes of diseases. Now
that potential therapies have been developed, one would hope
for more open communication. This will likely occur through
public pressure on Congress. I feel sorry for patients who
have been led into thinking that stealth-adapted viruses do
not exist. Instead of a major Public Health endeavor to
control these infections, the emphasis has gone to
politically less challenging explanations such as mercury
causing autism, depleted uranium causing Gulf War Syndrome;
toxins causing chronic fatigue; Borrelia causing so called
chronic Lyme disease, etc. Simple testing by Public Health
authorities would confirm the existence of stealth-adapted
viruses; some of which originated from the cytomegalovirus
of African green monkeys
Is more information available on a web site. Yes the address
is www.s3support.com
Would additional financial support help in pursuing stealth
viruses, ACE pigments and clinical trials.
Answer.
Yes. The Center for Complex Infectious Diseases is part of
S3Support, a Public 501(c) Charity. Donations are always
welcome. Funding would also help with a nationwide movement
towards more rational allocation of health resources. There
are structural flaws in both orthodox and
complimentary/alternative approaches to medeical care. I am
using the term Progressive Medicine as a framework to
incorporate energy based
therapeutic modalities.
I hope this information is helpful. Kind regards, W. John
Martin, M.D., Ph.D.
Posted November 4, 2005
to come Posted November 10, 2005
Dear April,
I was pleased to informally explain the "stealth-adapted
virus cause of autism" to a few attendees at the recent DAN
conference. Included were a presenter whose child had
improved on anti-viral therapy and a self proclaimed autism
celebrity. I also spoke briefly with Mr. David Kirby, author
of "Evidence of Harm." The DAN organizers have certainly
heard about stealth-adapted viruses but for whatever reason
the topic was again considered not suitable for public
presentation. "What we decide to present is decided by a
committee" someone told me and "they do not want to go
there." Possibly it is to avoid controversy. More likely,
many of the acknowledged experts are not really confident
virologists. It is easier for them to grasp and communicate
mercury contamination, biochemical pathways or
gastrointestinal problems than to discuss atypical viruses.
There is also a business aspect with vendors and clinicians
struggling to make a living out of autism. My trying to ta
lk science was not uncommonly interrupted with such comments
as "I'm not making nearly enough as I should in my practice"
or "Of course I'm entitled to make money by ordering
laboratory tests or profiting from prescribing overpriced
questionable supplements and therapeutic procedures." There
are certainly conscientious DAN doctors, some of whom are
themselves and/or have family members afflicted with
neuropsychiatric illnesses. These physicians, in particular,
should be speaking up against the obvious exploitation of
parents by some of their colleagues. They should also be
pushing the organizers for a more open discussion of
stealth-adapted viruses as the cause of autism; even thought
this issue may be less amenable to making money than the
scientifically unfounded concepts currently being hyped. On
a more positive note, I was able to recount the success of
using an energy based product in children in El Salvador
with severe diarrhea. Worldwide, this is a disease that
kills at least 10,000 children every day. The data will be
presented at an American Society of Tropical Medicine and
Hygiene meeting next month. I am hoping to get FDA approval
for the use of the product in the United States. Again, I am
facing a series of hurdles, this time protective of the
pharmaceutical industry, as opposed to concerns regarding
the economic welfare and status of supposedly autism
experts. The real tragedy is that by not discussing autism
as a disease caused by atypical stealth-adapted viruses,
there is no imperative for major Governmental intervention.
The requested Government expenditure of over $7 billion
dollars for a possible flu pandemic illustrates the
intensity of concern raised by infectious diseases that can
act indiscriminately throughout society. I would appreciate
if you could again ask parents in TAAP and other autism
support groups to simply request CDC testing of autistic
children for stealth-adapted viruses. In the interim, I will
try to expedite the process of having an effective energy
based product brought into the country. Kind regards, W.
John Martin, M.D., Ph.D.
Many thanks, John Martin
Posted by TAAP Nov. 23, 2005
Dear April,
Thank you for assisting me by directly contacting parents of
autistic children. As we discussed, a concerted parent-based
effort is needed to compel Government health authorities to
examine autistic children for stealth-adapted viruses. To
date, the Centers for Disease Control and Prevention (CDC)
has avoided using published protocols for culturing
stealth-adapted viruses. Simply stating that others have not
replicated research on these viruses is an inadequate excuse
for CDC not pursuing the epidemic of autism as an infectious
disease. Having visited CDC on several occasions, I am
convinced a better approach is to have the request for
testing come directly from a Congressman or Senator.
Politicians are answerable to their constituents but to date
they have not heard about stealth-adapted viruses. Parents
need to identify someone in Congress who is willing to set
up an informal meeting attended by myself and a virologist
from CDC. I believe I can do the rest.
I will be in Washington in mid December for a meeting of the
American Society of Tropical Medicine and Hygiene. I will
present data showing expedited recovery from infectious
diarrhea in children in El Salvador who received an energy
replenishing formulation. Progress in applying this type of
therapy to autistic children will be greatly facilitated
once autism is recognized as an atypical viral illness.
Moreover, efforts can be made to identify children at risk
for autism on the basis of being infected as newborns.
The issue for parents to convey to their representative is
that the failure of CDC to test autistic children for
stealth-adapted viruses is inexcusable especially since some
of these viruses arose from cytomegalovirus of the monkeys
used to produce polio vaccines. It can be further pointed
out that several licensed batches of polio vaccines have
been shown to contain DNA of African green monkey simian
cytomegalovirus. Testing has to include the culture methods
shown to be effective in detecting stealth-adapted viruses.
I have done these cultures in autistic children and know
that the results will be positive. It is long overdue for
CDC to step up to the plate and either do the testing or
explain to a politician why they choose not to do so.
Hopefully through cross-posting this request will rapidly
reach a majority of parents with autistic children. I would
appreciate receiving copies of any responses received from
Government officials. A suitable e-mail for this purpose is
stealthvirus@mail.com Information on stealth-adapted
viruses is available at
www.s3support.com Kind regards, W. John Martin, M.D.,
Ph.D.